COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
1
Department of Infectious Diseases, Jan Kochanowski University, 25-369 Kielce, Poland
2
College of Pharmacy, University of Houston, Houston, TX 77204, USA
3
Department of Infectious Diseases and Hepatology, Medical University of Białystok, 15-540 Białystok, Poland
4
Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Poznan, Poland
5
Integrated Science Association (ISA), Universal Scientific Education and Research Network (USERN), 60-806 Poznań, Poland
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Academic Editors: Nicholas G. Kounis and Peter Maple
Vaccines 2022, 10(8), 1223; https://doi.org/10.3390/vaccines10081223
Received: 28 June 2022
/
Revised: 25 July 2022
/
Accepted: 28 July 2022
/
Published: 30 July 2022
(This article belongs to the Special Issue Future of the COVID-19 Vaccinations in Humans and Animals: Novel Platforms, Antigens, Administration Routes, and Heterologous Combinations)
In the light of the lack of authorized COVID-19 vaccines adapted to the Omicron variant lineage, the administration of the first and second booster dose is recommended. It remains important to monitor the efficacy of such an approach in order to inform future preventive strategies. The present paper summarizes the research progress on the effectiveness of the first and second booster doses of COVID-19. It also discusses the potential approach in vaccination strategies that could be undertaken to maintain high levels of protection during the waves of SARS-CoV-2 infections. Although this approach can be based, with some shortcomings, on the first-generation vaccines, other vaccination strategies should be explored, including developing multiple antigen-based (multivariant-adapted) booster doses with enhanced durability of immune protection, e.g., through optimization of the half-life of generated antibodies.
View Full-Text
Keywords:
COVID-19; Omicron; booster; vaccine effectiveness
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Zarębska-Michaluk, D.; Hu, C.; Brzdęk, M.; Flisiak, R.; Rzymski, P. COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines 2022, 10, 1223. https://doi.org/10.3390/vaccines10081223
AMA Style
Zarębska-Michaluk D, Hu C, Brzdęk M, Flisiak R, Rzymski P. COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. Vaccines. 2022; 10(8):1223. https://doi.org/10.3390/vaccines10081223
Chicago/Turabian StyleZarębska-Michaluk, Dorota, Chenlin Hu, Michał Brzdęk, Robert Flisiak, and Piotr Rzymski. 2022. "COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects" Vaccines 10, no. 8: 1223. https://doi.org/10.3390/vaccines10081223
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
